Notícias e Atividades da Seres Therapeutics
Presença
Seres Therapeutics é uma das ...
Seres Therapeutics é uma empresa listada sob o símbolo MCRB (US).
Executivos
Veja o organograma con seus 23 executivos principais
Biografias mais buscadas da Seres Therapeutics
- Eric Shaff, Director, President and Chief Executive Officer
- Stephen Berenson, Chairman of the Board
- Kurt Graves, Director
Criar um alerta
para seguir os movimentos de executivos da Seres Therapeutics.
Biotecnologia
Seres Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).
Popular M&A news in Biotecnologia
- Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
- BioNTech has announced the acquisition of CureVac (publicado em 12 de junho de 2025).
- SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Seres Therapeutics
- Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference | Seres Therapeutics
- Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022 | Seres Therapeutics
- Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock | Seres Therapeutics
- Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection | Seres Therapeutics
- Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022 | Seres Therapeutics
- View more press releases Close
Redes sociais sobre Seres Therapeutics
- Seres Therapeutics na Wikipedia, Google News e Yahoo Finance
- Seres Therapeutics na LinkedIn, Twitter e YouTube
